WO2003040723A1 - Procede de rehabilitation de l'organisme en cas d'infection virale lente - Google Patents

Procede de rehabilitation de l'organisme en cas d'infection virale lente Download PDF

Info

Publication number
WO2003040723A1
WO2003040723A1 PCT/RU2002/000143 RU0200143W WO03040723A1 WO 2003040723 A1 WO2003040723 A1 WO 2003040723A1 RU 0200143 W RU0200143 W RU 0200143W WO 03040723 A1 WO03040723 A1 WO 03040723A1
Authority
WO
WIPO (PCT)
Prior art keywords
πρi
aids
chτο
sποsοb
βich
Prior art date
Application number
PCT/RU2002/000143
Other languages
English (en)
Russian (ru)
Inventor
Vitaly Vasilievich Tkachenko
Original Assignee
Vitaly Vasilievich Tkachenko
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vitaly Vasilievich Tkachenko filed Critical Vitaly Vasilievich Tkachenko
Publication of WO2003040723A1 publication Critical patent/WO2003040723A1/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV

Definitions

  • the invention is subject to the detection of viral disease and medical immunogenetics in connection with the results of the development of a biocommunicational disease.
  • a very important task is to prevent the development of immune deficiencies (IDs) as a phenomenon and, at the same time, as a result of the development mechanism of AI.
  • IDs immune deficiencies
  • the virus In the first place, the virus is generally occupied by the causative agent, the causative agent of the human immunodeficiency virus (HIV), the terminal stage of the disease, and the This is the first ⁇ And not with the local foci of infection, but with a real epidemic, or rather, a pandemic, with civilization in the XX century.
  • HIV human immunodeficiency virus
  • ⁇ a ⁇ im ⁇ b ⁇ az ⁇ m is ⁇ dya of bi ⁇ in ⁇ matsi ⁇ nny ⁇ za ⁇ n ⁇ me ⁇ n ⁇ s ⁇ ey in ⁇ e ⁇ tsi ⁇ nn ⁇ g ⁇ ⁇ tsessa vi ⁇ usn ⁇ y e ⁇ i ⁇ l ⁇ gii and ⁇ inimaya v ⁇ attention i ⁇ ⁇ s ⁇ benn ⁇ s ⁇ i ⁇ i ⁇ ICH-in ⁇ e ⁇ tsii-AIDS, we have been ⁇ az ⁇ ab ⁇ ana and ⁇ sv ⁇ ena s ⁇ ema ⁇ dn ⁇ nedeln ⁇ g ⁇ tsi ⁇ la in ⁇ azhd ⁇ m ⁇ dn ⁇ mesyachn ⁇ m ⁇ u ⁇ se lecheby ⁇ v ⁇ zdeys ⁇ vy, ⁇ aya ⁇ edelyalas ⁇ sled ⁇ va ⁇ eln ⁇ s ⁇ yu ⁇ tsedu ⁇ , ⁇ e ⁇ echislenny ⁇ below
  • 1 ml of this suspension contained 1.5 ⁇ 10 4 - 1.8 ⁇ 10 5 particles ⁇ ICH; 1 ml of this suspension was injected into the peripheral ear vein, each of which was taken in an experiment in the body, weighing only 4 - 5 kg and only twice infected with plasma.
  • one of the group has 5 live (G ⁇ u ⁇ a ⁇ e ⁇ vaya) is ⁇ lz ⁇ vali d ⁇ n ⁇ ami with an ⁇ i ⁇ elami ( ⁇ ) ⁇ iv chuzhe ⁇ dny ⁇ an ⁇ igen ⁇ v ( ⁇ g) s ⁇ edi ⁇ y ⁇ were in ⁇ itsi ⁇ uyuschie ⁇ ICH-vi ⁇ i ⁇ ny in is ⁇ dn ⁇ y ( ⁇ -) ⁇ me, i ⁇ v ⁇ zm ⁇ zhnye mu ⁇ an ⁇ y and i ⁇ ⁇ entsialnye ass ⁇ tsian ⁇ y vi ⁇ usn ⁇ y and / or mi ⁇ bn ⁇ y ⁇ i ⁇ dy in usl ⁇ viya ⁇ is ⁇ lz ⁇ vaniya s ⁇ anda ⁇ n ⁇ y methods of hypeimmunization with a suspended suspension of alien ancient animals.
  • BPS BPS
  • HI-virions and their mutants in the sensible electronic divisions were recognized using immuno-assay analysis and compu- In experienced animals after 7 - 8 cases of infection in the patient, such a clinical illness was detected, such as diarrhea, a generalized ⁇ a ⁇ im ⁇ b ⁇ az ⁇ m, m ⁇ deli ⁇ uemaya only ⁇ m ⁇ schyu massi ⁇ vanny ⁇ d ⁇ z in ⁇ e ⁇ a " ⁇ bivayuschi ⁇ " ⁇ i ⁇ dny immuni ⁇ e ⁇ in ⁇ li ⁇ v, ⁇ edva ⁇ i ⁇ eln ⁇ za ⁇ azhenny ⁇ ⁇ s ⁇ lazm ⁇ z ⁇ m, K ⁇ ICH-in ⁇ e ⁇ tsii ⁇ zv ⁇ lyae ⁇ ul ⁇ vi ⁇ ⁇ izna ⁇ i s ⁇ avni ⁇ eln ⁇ ⁇ zdneg ⁇ e ⁇ a ⁇ a ⁇ azvi ⁇ iya ⁇ ICH-in ⁇ e ⁇ tsii not ⁇ zv
  • P ⁇ i is ⁇ y ⁇ anii in ⁇ g ⁇ va ⁇ ian ⁇ a s ⁇ s ⁇ ba, ⁇ sn ⁇ vann ⁇ g ⁇ on us ⁇ anenii elemen ⁇ v in ⁇ e ⁇ tsi ⁇ nn ⁇ -ass ⁇ tsia ⁇ ivn ⁇ g ⁇ ⁇ m ⁇ le ⁇ sa with ⁇ m ⁇ schyu U ⁇ - ina ⁇ ivi ⁇ vaniya, is ⁇ lz ⁇ vali e ⁇ s ⁇ a ⁇ alnuyu ⁇ chn ⁇ -tsi ⁇ ulya ⁇ nuyu sis ⁇ emu (E ⁇ STSPD) ⁇ iginaln ⁇ y ⁇ ns ⁇ u ⁇ tsii where the main bl ⁇ m was zmeevi ⁇ vy a ⁇ g ⁇ n ⁇ u ⁇ n ⁇ va ⁇ tsevy ⁇ blucha ⁇ el (Z ⁇ ).
  • P ⁇ i is ⁇ y ⁇ anii va ⁇ ian ⁇ a s ⁇ s ⁇ ba, ⁇ sn ⁇ vann ⁇ g ⁇ on us ⁇ anenii ⁇ ICH, eg ⁇ mu ⁇ an ⁇ v and eg ⁇ ass ⁇ tsian ⁇ v with ⁇ m ⁇ schyu immun ⁇ chis ⁇ i ⁇ v ⁇ a E ⁇ STSPD, ⁇ azhd ⁇ e of na ⁇ izi ⁇ vanny ⁇ (e ⁇ il ⁇ vym e ⁇ i ⁇ m) zhiv ⁇ ny ⁇ ⁇ i ⁇ si ⁇ vali vyaz ⁇ ami for la ⁇ y ⁇ deln ⁇ y d ⁇ s ⁇ e ⁇ - ⁇ la ⁇ e, ⁇ a ⁇ and ⁇ y ⁇ a ⁇ ⁇ i is ⁇ y ⁇ anii U ⁇ - ina ⁇ ivi ⁇ vaniya and They vivisected in a private fashion, free of charge in the anterior zone for a sympathetic introduction, and they were in danger of losing their health.
  • ⁇ ⁇ anyule with ⁇ av ⁇ y s ⁇ ny ⁇ ela zhiv ⁇ n ⁇ g ⁇ was ⁇ is ⁇ edinen ⁇ s ⁇ e ⁇ iliz ⁇ vanny ⁇ lis ⁇ i ⁇ lny hose- ⁇ ub ⁇ a going ⁇ a ⁇ a ⁇ a ⁇ u ⁇ eches ⁇ venn ⁇ y m ⁇ deli P ⁇ -0.5, was ⁇ y m ⁇ di ⁇ itsi ⁇ van us because ne ⁇ b ⁇ dim ⁇ s ⁇ i ⁇ susches ⁇ vleniya with eg ⁇ ⁇ m ⁇ schyu ⁇ tsedu ⁇ y IG ⁇ with ⁇ imeneniem immun ⁇ lis ⁇ i ⁇ ln ⁇ y ⁇ len ⁇ i with s ⁇ zdavaem ⁇ m ⁇ i e ⁇ m g ⁇ avi ⁇ atsi ⁇ nn ⁇ m ⁇ le.
  • P ⁇ e ⁇ a ⁇ a ⁇ s ⁇ , ⁇ luchenny in ⁇ ezul ⁇ a ⁇ e gi ⁇ e ⁇ immunizatsii ⁇ li ⁇ v (from ⁇ ya ⁇ y and shes ⁇ y g ⁇ u ⁇ y ⁇ d ⁇ y ⁇ ny ⁇ zhiv ⁇ ny ⁇ , is ⁇ lzuemy ⁇ s ⁇ ve ⁇ s ⁇ venn ⁇ for ⁇ vedeniya ⁇ tsedu ⁇ y with ⁇ imeneniem IG ⁇ and ⁇ tsedu ⁇ y with ⁇ imeneniem GCI) ⁇ vyu za ⁇ azhenny ⁇ ⁇ ICH ⁇ li ⁇ v (from ⁇ n ⁇ ln ⁇ y, ⁇ es ⁇ ⁇ e ⁇ v ⁇ y g ⁇ u ⁇ y) ⁇ i ⁇ si ⁇ vali in zhes ⁇ i ⁇ usl ⁇ viya ⁇ on a carrier in the form of an active film for an IHF or on an active film aid for an IHF.
  • IGF-IGS IGF-IGS
  • the vaccine was introduced ' on the fifth day of the cycle of the occupational exposure.
  • ⁇ ⁇ n ⁇ ln ⁇ y (v ⁇ y) g ⁇ u ⁇ y ⁇ d ⁇ y ⁇ ny ⁇ ⁇ li ⁇ v with ⁇ s ⁇ lazm ⁇ z ⁇ m on ⁇ e ⁇ i - che ⁇ ve ⁇ ye su ⁇ i ⁇ sle massivn ⁇ g ⁇ za ⁇ azheniya ⁇ ICH-s ⁇ de ⁇ z haschim ma ⁇ e ⁇ ial ⁇ m of d ⁇ n ⁇ s ⁇ y ⁇ ICH-in ⁇ itsi ⁇ vann ⁇ y ⁇ vi, ⁇ sle d ⁇ bavleniya ⁇ it a ⁇ iva ⁇ a ⁇ e ⁇ li ⁇ atsii ⁇ ICH as 0.015 mg / ⁇ g li ⁇ ilizi ⁇ vann ⁇ g ⁇ ⁇ e ⁇ a ⁇ a ⁇ a B ⁇ PS (in ⁇ assche ⁇ e on weight lively), in most cases, noted the development of diarrhea, which should be avoided by the intravenous administration
  • Example 3 The division of the HIV-binding activity in the C ⁇ 4 drug under the conditions of its subsequent use to enhance the HIV-binding activity of the immune system is immune.
  • a weight of 50 mg of C ⁇ 4 preparation is dissolved in 100 ml of an industrial (0.85%) solution of sodium chloride on a thick buffer (0D5 ⁇ ; ⁇ 7.1 - 7.2).
  • ⁇ bychn ⁇ is ⁇ lzuem ⁇ g ⁇ for s ⁇ anda ⁇ n ⁇ g ⁇ ⁇ es ⁇ i ⁇ vaniya ⁇ i diagn ⁇ s ⁇ i ⁇ e AIDS ( ⁇ ICH- ⁇ ) and vn ⁇
  • Waste oil and oil inks were incubated at 37 ° ⁇ during the course of one day. After the temperature, all the products were heated in a water bath at 40 ° C, except for the installation of a cold storage hood. For chilled products, add hinges of sour acid ammonia to a 65% increase and ⁇ 6.5; in the basic devices and in the control unit ⁇ ° 2, a sloping-shaped garden was separable, separated by centrifugation (3000 ⁇ ⁇ , 15 minutes, + 4 ° C). At the same time, the processes of ⁇ ° 1 and ⁇ ° 3 were not detected, since there was no disruption of ammunition in these plants.
  • Pe ⁇ e ⁇ as ⁇ v ⁇ ennaya ⁇ a ⁇ tsiya ⁇ etsi ⁇ i ⁇ a ⁇ a of ⁇ b with S ⁇ 4 - ⁇ e ⁇ a ⁇ a ⁇ m s ⁇ de ⁇ zhala 82-86) is ⁇ dn ⁇ y ⁇ ntsen ⁇ atsii ⁇ of s ⁇ s ⁇ ava d ⁇ bavlenn ⁇ g ⁇ ⁇ bam ⁇ ICH ⁇ -1-diagn ⁇ s ⁇ i ⁇ uma, ⁇ gda ⁇ a ⁇ s ⁇ ve ⁇ s ⁇ vuyuschie ⁇ a ⁇ tsii su ⁇ e ⁇ na ⁇ an ⁇ a of ⁇ e ⁇ same ⁇ b s ⁇ de ⁇ zhali ⁇ l ⁇ 14 - 18% of is ⁇ dn ⁇ y ⁇ ntsen ⁇ atsii ⁇ same ⁇ g ⁇ diagnosis.
  • EXAMPLE 7 For freeing an organism from the elements of a start to HIV infection, it is also possible to prevent the occurrence of these elements in a business.
  • GCI is ⁇ lz ⁇ vali ⁇ l ⁇ n ⁇ u ⁇ az ⁇ v ⁇ g ⁇ ⁇ lz ⁇ vaniya, ⁇ i ⁇ a ⁇ ma ⁇ g ⁇ a ⁇ iches ⁇ y, ⁇ bem ⁇ m 300 ml of ⁇ z ⁇ achn ⁇ g ⁇ bestsve ⁇ n ⁇ g ⁇ ⁇ las ⁇ i ⁇ a, ⁇ uyu ne ⁇ l ⁇ n ⁇ zag ⁇ uzhali immun ⁇ s ⁇ ben ⁇ m, n ⁇ si ⁇ elem in ⁇ slednem served a ⁇ ivi ⁇ vanny s ⁇ ben ⁇ ⁇ eches ⁇ venn ⁇ y 'ma ⁇ i ⁇ S on ⁇ m ⁇ valen ⁇ n ⁇ ⁇ i ⁇ si ⁇ vali s ⁇ as ⁇ chischenn ⁇ y li ⁇ ilizi ⁇ vann ⁇ y gamma gl ⁇ bulin ⁇ v ⁇ y ⁇ a ⁇ tsii from the
  • ⁇ dn ⁇ v ⁇ emenn ⁇ ⁇ b ⁇ aba ⁇ yvayu ⁇ E ⁇ STSPD in s ⁇ b ⁇ ann ⁇ m form s ⁇ e ⁇ ilnym ⁇ as ⁇ v ⁇ m ge ⁇ a ⁇ ina (10000 I ⁇ 400 ml ⁇ izi ⁇ l ⁇ giches ⁇ g ⁇ ⁇ as ⁇ v ⁇ a ⁇ l ⁇ ida na ⁇ iya) and ⁇ it ⁇ d ⁇ lyuchayu ⁇ ⁇ atsien ⁇ a simme ⁇ ichnym introduction eg ⁇ vein needle- ⁇ a ⁇ e ⁇ e ⁇ v ( ⁇ anyuley) with ⁇ v ⁇ dyaschim and ⁇ iv ⁇ dyaschim ⁇ lis ⁇ i ⁇ lnymi- ⁇ ub ⁇ ami hoses.
  • ⁇ e ⁇ yae maya v ⁇ v ⁇ emya ⁇ tsedu ⁇ IG ⁇ -GCI ⁇ lazma s ⁇ suspended therein vi ⁇ usami and / or mi ⁇ ganizmami replaced ⁇ sle IG ⁇ ⁇ e ⁇ i ⁇ lazmy ⁇ vi ⁇ avnym ⁇ ⁇ bemu (200 - 250 ml) ⁇ liches ⁇ v ⁇ m ⁇ lazm ⁇ zameni ⁇ elya, ⁇ e ⁇ i ⁇ lazmy ⁇ vi in ⁇ ezul ⁇ a ⁇ e ⁇ izvedenn ⁇ y GCI were meny ⁇ e ⁇ ⁇ bemu (150 - 200 ml), but also needed to be replaced by a plasma substitute in general, it was necessary to enter 20
  • the patient was subject to an increase in the incidence of neglect and, most importantly, the patient ⁇ a ⁇ uyu immun ⁇ e ⁇ tsiyu in tselya ⁇ v ⁇ ss ⁇ an ⁇ vleniya na ⁇ ushenn ⁇ g ⁇ immun ⁇ entsiala and eg ⁇ u ⁇ e ⁇ leniya at ⁇ atsien ⁇ a ⁇ susches ⁇ vlyali with ⁇ m ⁇ schyu ⁇ m ⁇ ensa ⁇ n ⁇ y ⁇ ans ⁇ lan ⁇ atsii in ⁇ s ⁇ ny m ⁇ zg g ⁇ udiny ⁇ atsien ⁇ a in ⁇ sn ⁇ vn ⁇ m on account yuny ⁇ ⁇ m-s ⁇ v ⁇ l ⁇ vy ⁇ ⁇ edshes ⁇ venni ⁇ v ⁇ ley ⁇ ezu ma ⁇ ag ⁇ v and ⁇ el ⁇ e ⁇ ny ⁇ ⁇ -lim ⁇ tsi ⁇
  • Immunotherapy was unthinkable without the following immunoactivation procedures (immunostimulation) with the introduction of a patient with an auto-vaccine.
  • P ⁇ imenenie au ⁇ va ⁇ tsiny ⁇ azal ⁇ s tseles ⁇ b ⁇ aznym in ⁇ m ⁇ n ⁇ shenii, ch ⁇ ⁇ na in izves ⁇ n ⁇ y me ⁇ e s ⁇ s ⁇ bna ⁇ vliya ⁇ to "immun ⁇ l ⁇ giches ⁇ y ⁇ tsessing" in ⁇ matsii ⁇ b ⁇ s ⁇ benn ⁇ s ⁇ ya ⁇ chuzhe ⁇ dny ⁇ ⁇ g, ⁇ ien ⁇ i ⁇ uya ⁇ ans ⁇ lan ⁇ i ⁇ vannye ⁇ ans ⁇ lan ⁇ i ⁇ vannye elemen ⁇ y PP ⁇ and a ⁇ ivi ⁇ uya i ⁇ ⁇ iv elemen ⁇ v in ⁇ e ⁇ tsi ⁇ nn ⁇ -ass ⁇ tsia
  • Immunity is used in accordance with Example 1. Immunity is used in accordance with Example 1.
  • the treatment is in the form of an emergency treatment, and each treatment consists of four weekly cycles if: The duration of each of these procedures is 1.5 - 2 hours per week per week and the total volume of transfusion through the ESCAP is practical throughout 22
  • Example 11 The intrinsic transplantation of drugs and their effects from the PP add and thereby terminate the intrinsic therapy.
  • ⁇ azhdaya ine ⁇ tsiya au ⁇ va ⁇ tsiny in usl ⁇ viya ⁇ izg ⁇ vleniya individualizi ⁇ vann ⁇ y ⁇ liva ⁇ tsiny smyv ⁇ m gem ⁇ ul ⁇ u ⁇ with aga ⁇ v ⁇ y s ⁇ edy, ⁇ sle ⁇ seva it ⁇ 0.4 - 0.5 ml ⁇ vi ⁇ agree ⁇ g ⁇ ⁇ atsien ⁇ a, in ⁇ ubatsii ⁇ i 37 ° C ⁇ echenii ⁇ e ⁇ su ⁇ , ⁇ bedinyaemym ⁇ ed U ⁇ -ina ⁇ ivatsiey with In the case of foreign embryos, after the introduction of allantis in them, 0.4 - 0.5 ml of the same patient and similar incubation, see above), there is no inconceivable incidence.
  • the duration of treatment in the course of the onset of AIDS is 2 to 3 months; that is, there are 2 to 3 courses of treatment due to immunodeficiency.
  • Example 12 The use of the method and the virus in case of a HP infection. The treatment is carried out in accordance with Examples 10 and 11; in the event of a viral illness, the general course of treatment should be repeated. The cases identified are indicative of a serious negative reaction to the use of medical devices in the event of a medical treatment.
  • Example 13 The use of the method for both static and asymptomatic forms of HIV infection identified on the basis of anamnesis, epidemiological data and research data. In order to avoid the development of an infectious process or the development of a persistent treatment, the treatment is carried out in accordance with Examples 10 and 11.
  • Example 14 The use of the method for the late stages of HIV infection, AIDS, and obvious clinical manifestations of AIDS in the form of a genetically 23
  • GPL Systemic lymphadenopathy
  • the patients After receiving a general treatment of the patient, the patients are in any
  • Example 15 Patient D. X., a 25-year-old man from New York State, is a university student. AIDS was diagnosed on the basis of a positive test for the presence in the open. He was carried away by the smoking of marijuana, so he decided not to inject it. It is noted that there is an increase in mental inertia, a feeling of physical weakness and trauma, and a quick fatigue is absent. S ⁇ glasn ⁇ is ⁇ dn ⁇ mu analysis ⁇ liniches ⁇ y ⁇ a ⁇ iny ⁇ vi, y X. D.
  • HIV infection HIV infection, asymptomatic form, AIDS in the clinical stage of HIV 1 " (for the settings of the United States, 1991) or inpatient phase-positive condition?
  • HIV infection asymptomatic AIDS in the clinical phase of HIV + or HIV infection, a type of HIV-positive infection After the paths of immuno-exposure to our method, based on the use of immunodefenses in the heart of the patient with immunodeficiency hormones and hereditary diseases 25
  • Example 17 Patient W.J., an unmarried man aged 35 years from the state of Delaware, a poor model who had been ill, was relieved of casualties. The results of these tests were found to be positive. Homosexualism suffers. He underwent acyclic treatment. It has a soulful and physical deafness, it disturbs good at night, it experiences a loss. The ultimate AIDS test is positive. Clinical analysis of the disease noted leukenia and moderate monotonism.
  • HIV infection asymptomatic AIDS in the clinical phase of HIV + or HIV infection, a type of HIV-positive infection
  • P ⁇ i ⁇ mene treatment and ⁇ sleduyuschem 10 le ⁇ nem monitoring with monthly ⁇ bsled ⁇ vaniyami with ⁇ m ⁇ schyu s ⁇ anda ⁇ ny ⁇ ⁇ es ⁇ v AIDS and ⁇ dn ⁇ v ⁇ emennymi ⁇ liniches ⁇ imi analyzes ⁇ vi ⁇ mecheny us ⁇ ychivye ⁇ itsa ⁇ elnye ⁇ es ⁇ y AIDS s ⁇ v ⁇ zhdaemye ⁇ edeleniem m ⁇ aza ⁇ eley ⁇ vi, svide ⁇ els ⁇ v ⁇ vavshimi ⁇ it n ⁇ malizatsii.
  • Example 18 Patient ⁇ . ⁇ . ⁇ ., An unmarried man at the age of 28 years from the state of Delaware, a commissar of one of the largest military enterprises. The result of the standard AIDS test turned out to be positive with the simultaneous confirmation of the diagnosis of “hepatitis ⁇ ”. Complaints of depression, distress, troubled sleep, nightly sleeps, poor health, and the feeling of sadness, loss of heart. An extensive investigation is underway. 26
  • HIV infection asymptomatic AIDS in the clinical phase of HIV + or HIV infection
  • a type of HIV-positive infection Static phenomena of the trans-acquired genetics ⁇ ? P ⁇ sle dvu ⁇ ⁇ u ⁇ s ⁇ v ambula ⁇ n ⁇ g ⁇ treatment ⁇ s ⁇ anda ⁇ n ⁇ y s ⁇ eme ⁇ imeneniya s ⁇ s ⁇ ba, ⁇ sn ⁇ vann ⁇ g ⁇ on immun ⁇ chis ⁇ e ⁇ vi in E ⁇ STSPD ⁇ e ⁇ emenn ⁇ me ⁇ dami IG ⁇ and GCI in ⁇ mbinatsii with gem ⁇ s ⁇ btsiey and d ⁇ lnenn ⁇ g ⁇ ⁇ sleduyuschimi ⁇ tsedu ⁇ ami ⁇ m ⁇ ensa ⁇ n ⁇ y immun ⁇ e ⁇ tsii and immun ⁇ s ⁇ imulyatsii and ⁇ a ⁇ zhe vnu ⁇ ivennymi administrations 40% -n
  • Example 19 Patient D. G. G., an obscure man, 37 years old from New York State, an enthusiastic businessman-owner of a company. A conventional AIDS standard test was found to be beneficial. I didn’t notice any health problems in the USA after two months after I found out that there was a positive AIDS test in the United States that I didn’t have any health problems.
  • Example 20 Patient Yu. X. X., 39 years. The standard AIDS test for the patient was negative. While asserting that he was infected with AIDS, Yu. X. X. did not report any complaints; Yu. X. X. was doubling the process of "promoting the virus.”
  • Example 21 Patient ⁇ . J. ⁇ ., An unmarried man of 26 years, is a student at the University of Pennsylvania. Complaints of the feeling of fatigue, fatigue, fatigue, mental stress, insomnia and poor performance. There are no errors in the general survey, including a neurological status, not found; A simple AIDS standard test is good.
  • HIV infection asymptomatic AIDS in the clinical phase of HIV +, or HIV infection, a type of HIV-positive infection?
  • immun ⁇ sis ⁇ emy was us ⁇ eshn ⁇ is ⁇ lz ⁇ van us and ⁇ i treatment with ⁇ imeneniem individualizi ⁇ vann ⁇ y ⁇ izg ⁇ vleniyu and purpose ⁇ liva ⁇ tsiny (vnu ⁇ ivenn ⁇ ⁇ a ⁇ elnym s ⁇ s ⁇ b ⁇ m) ch ⁇ illyus ⁇ i ⁇ ue ⁇ sya nizhe ⁇ ivedennymi ⁇ ime ⁇ ami on ⁇ sn ⁇ ve ⁇ a ⁇ i ⁇ vy ⁇ is ⁇ of is ⁇ y b ⁇ lezni ⁇ e ⁇ lecheny ⁇ contact with ⁇ atsien ⁇ v ⁇ m ⁇ schyu labor ⁇ g ⁇ va ⁇ ian ⁇ a s ⁇ s ⁇ ba v ⁇ zdeys ⁇ viya.
  • Example 22 Patient ⁇ ., An unmarried man at the age of 25 years old, a citizen of Russia. There is a constant sense of physical weakness when there is no loss of food or fatigue, there is a constant restlessness, an indulged sleep; It is necessary to observe how much the HHI infection is, when the patient receives treatment with the name ⁇ .
  • Diagnosis HIH infection in the clinical stage I - II, pRESPID, generalized chronic systemic lymphadenopathy (GPL). Herbal infection. ⁇ réelle ⁇ mania.
  • Example 23 Patient ⁇ ., A good man at the age of 20 years, a citizen of Russia. With a comprehensive survey: the total condition is negative, active. Housework; mucous membranes of the mouth, nasopharynx and are overwhelmed and bent. A large temperature (body temperature 37.4 ° ⁇ ). ⁇ light scattered fuzzy short-circuit on quick-breathing; Reliable lymph nodes are not available; The area is painless. The function of the gastrointestinal tract is not impaired; The liver and spleen are not enlarged. A positive AIDS test is good; For clinical analysis of the disease: leukocytes 2.58 ⁇ 10 9 / l, ⁇ 4 0.05 ⁇ 10 9 / l, ⁇ 12 mm / hour. Sowing space on steadiness gave growth to a stately growth; When researching the field, pneumocysts are revealed, also identified in feces; urine analysis without pathology.
  • Diagnosis HIV infection, AIDS-infection in clinical stage II - S. Pneumocystis. ⁇ ⁇ ezul ⁇ a ⁇ e ⁇ e ⁇ ⁇ vedenny ⁇ ⁇ u ⁇ s ⁇ v immun ⁇ v ⁇ zdeys ⁇ viya, ⁇ sn ⁇ vann ⁇ g ⁇ on vnu ⁇ ivenn ⁇ m administered ⁇ a ⁇ elnym s ⁇ s ⁇ b ⁇ m (s d ⁇ bavleniem an ⁇ i ⁇ agulyan ⁇ a) individualizi ⁇ vann ⁇ y ⁇ izg ⁇ vleniyu and ⁇ imeneniyu ⁇ liva ⁇ tsiny in s ⁇ ve ⁇ s ⁇ vii with ⁇ az ⁇ ab ⁇ ann ⁇ y ⁇ ln ⁇ y s ⁇ anda ⁇ n ⁇ y s ⁇ em ⁇ y ⁇ v ⁇ dimy ⁇ tsi ⁇ l ⁇ v ⁇ a ⁇ g ⁇ treatment d ⁇ lnenn ⁇ g ⁇ vnu ⁇ ivenn
  • Example 24 Patient L., a married meat seller at the age of 30 years, a citizen of Russia. L. was found to have a positive AIDS standard test, and he agreed to the treatment.
  • a positive AIDS standard test When examining the clinical condition of the disease, there was a marked decrease in the number of eruptions for patients with 27 g / l, a decrease in the number of leukemia to 3.5 ⁇ 10 9 / l; The content of the cells was 338 x 10 8 / l, the number of cells was 15), SB 4 -cells - 26 / mm 3 of the box.
  • ⁇ ⁇ ICH-in ⁇ e ⁇ tsii and AIDS were usl ⁇ viya ⁇ ⁇ imeneniya immun ⁇ m ⁇ dulya ⁇ a as ami ⁇ sina were is ⁇ lz ⁇ vany ⁇ li ⁇ i males ves ⁇ m ⁇ ⁇ 4.5 - 5.5 ⁇ g in ⁇ edva ⁇ i ⁇ eln ⁇ za ⁇ azhennye ⁇ e ⁇ aln ⁇ ⁇ s ⁇ lazm ⁇ z ⁇ m and za ⁇ em za ⁇ azhennye vnu ⁇ ivenn ⁇ massi ⁇ vann ⁇ y d ⁇ z ⁇ y ⁇ ICH - s ⁇ de ⁇ zhavsheg ⁇ ma ⁇ e ⁇
  • the infectious HIV-infected material was delivered from the processed AIDS tests for blood baths, which resulted in hemodisation, which resulted in a dry process. recovery of salt; 1 ml of the obtained suspension with the addition of an active activator of the RPI in the form of BPA was injected into the external ear vein.
  • ⁇ ⁇ ivedenn ⁇ y below ⁇ ablitse 1 ⁇ azany data ⁇ i ⁇ sche ⁇ e s ⁇ a ⁇ yavleniya ⁇ izna ⁇ v e ⁇ s ⁇ e ⁇ imen ⁇ aln ⁇ y ⁇ ICH-in ⁇ e ⁇ tsii at ⁇ li ⁇ v starting s ⁇ day za ⁇ azheniya massive d ⁇ zami ⁇ ICH in s ⁇ s ⁇ avlenii data ⁇ n ⁇ si ⁇ eln ⁇ ⁇ n ⁇ ln ⁇ y g ⁇ u ⁇ y zhiv ⁇ ny ⁇ of ⁇ ya ⁇ i ⁇ li ⁇ v (in ⁇ ablitse not ⁇ azany) in ⁇ y treatment is ⁇ v ⁇ dil ⁇ s.
  • the familiar protein known as acid, is the amino acid investigation, i.e. ⁇ ⁇ e ⁇ vichn ⁇ y s ⁇ u ⁇ u ⁇ e, iden ⁇ ichen ⁇ i ⁇ n ⁇ d ⁇ bn ⁇ mu bel ⁇ u ( ⁇ g ⁇ s) lishenn ⁇ mu ⁇ a ⁇ genny ⁇ , in ⁇ e ⁇ tsi ⁇ nny ⁇ sv ⁇ ys ⁇ v, ⁇ edelyayuschemu, ⁇ a ⁇ ⁇ lagayu ⁇ , n ⁇ maln ⁇ e ⁇ un ⁇ tsi ⁇ ni ⁇ vanie ⁇ le ⁇ Pu ⁇ ine in m ⁇ zzhech ⁇ e mle ⁇ i ⁇ ayuschi ⁇ in [21].
  • the private infection which is just for this product, the adapter, which has been installed at the factory, made it possible for 2 to 3 months to consume the user without any charge.
  • Te same s ⁇ i, ⁇ ye were u ⁇ azany v ⁇ e ⁇ n ⁇ si ⁇ eln ⁇ in ⁇ ubatsi ⁇ nn ⁇ g ⁇ ⁇ e ⁇ i ⁇ da and ⁇ n ⁇ si ⁇ eln ⁇ ⁇ d ⁇ maln ⁇ g ⁇ ⁇ e ⁇ i ⁇ da, microseconds from among ⁇ e ⁇ v ⁇ y and v ⁇ y g ⁇ u ⁇ and microseconds from among ⁇ e ⁇ ey and che ⁇ ve ⁇ y g ⁇ u ⁇ y ( ⁇ ⁇ ya ⁇ za ⁇ azhenny ⁇ zhiv ⁇ ny ⁇ ) were ⁇ dve ⁇ gnu ⁇ y, s ⁇ ve ⁇ s ⁇ venn ⁇ , e ⁇ s ⁇ a ⁇ aln ⁇ mu binding ⁇ i ⁇ na in usl ⁇ viya ⁇ GCI and under conditions of HUD, it is rigidly fixed on a fixed fuselage, imbued, as noted, from the uncontrolled wedge, it is contaminated.
  • Intracerebral administration of the device included each of the live parts in the fixed state of the separate electronic keypad with a left-hand side panel ⁇ s ⁇ alnye 10 zhiv ⁇ ny ⁇ ( ⁇ 5 microseconds ⁇ s ⁇ avshi ⁇ sya in ⁇ e ⁇ v ⁇ y and v ⁇ y g ⁇ u ⁇ a ⁇ , ⁇ aznivshi ⁇ sya ⁇ ⁇ u ⁇ yam administration ⁇ i ⁇ na ⁇ i za ⁇ azhenii) ⁇ a ⁇ zhe in na ⁇ izi ⁇ vann ⁇ m s ⁇ s ⁇ yanii ⁇ d ⁇ lyuchili ⁇ E ⁇ STSPD, n ⁇ with ⁇ m ⁇ schyu igl- ⁇ a ⁇ e ⁇ e ⁇ v ( ⁇ anyuley) vvedenny ⁇ ⁇ azhd ⁇ mu zhiv ⁇ n ⁇ mu in suba ⁇ a ⁇ n ⁇ idaln ⁇ e ⁇ s ⁇ ans ⁇ v ⁇ s ⁇ inn ⁇ g ⁇
  • intralumbal intralumbal, and intrinsically effective, especially on the part of the foreign party of the left side of the left ventricular, is used ⁇ a ⁇ im ⁇ b ⁇ az ⁇ m all zhiv ⁇ nye in e ⁇ s ⁇ e ⁇ imen ⁇ e bshi ⁇ as ⁇ edeleny ⁇ v ⁇ smi ⁇ dg ⁇ u ⁇ am, ⁇ aznivshi ⁇ sya not ⁇ l ⁇ ⁇ tselev ⁇ mu is ⁇ lz ⁇ vaniyu i ⁇ in e ⁇ s ⁇ e ⁇ imen ⁇ e, n ⁇ and ⁇ ⁇ s ⁇ benn ⁇ s ⁇ yam introducing them za ⁇ azhayuscheg ⁇ ma ⁇ e ⁇ iala and ⁇ d ⁇ lyucheniya ⁇ E ⁇ STSPD ⁇ d ⁇ y ⁇ ny ⁇ zhiv ⁇ ny ⁇ in tselya ⁇ ⁇ b ⁇ ab ⁇ i ⁇ vi or S ⁇ ZH in usl ⁇ viya ⁇ treatment
  • the ESCAP used in the case of IHC in principle was similar to that used by us for the immuno-linking of the elements of the pathogenesis of HIV infection by the IHL method. The differences only occurred in mainstream systems of the main units and connections of comparable systems and, consequently, in the regimes of their use.
  • ⁇ ⁇ isshaem ⁇ m below e ⁇ s ⁇ e ⁇ imen ⁇ e on- ⁇ a ⁇ e ⁇ e ⁇ y needle ( ⁇ anyuli) were nasazhany (1) ⁇ v ⁇ dyaschaya ⁇ v ⁇ na ⁇ izi ⁇ vann ⁇ y microseconds, for ⁇ i ⁇ si ⁇ vann ⁇ y ⁇ nechn ⁇ s ⁇ i on ⁇ lash ⁇ e, and (2) it ⁇ iv ⁇ dyaschaya ⁇ ⁇ b ⁇ ab ⁇ annuyu ⁇ v sili ⁇ n ⁇ vye ⁇ ub ⁇ i diame ⁇ m ⁇ 1,5 mm.
  • P ⁇ i izg ⁇ vlenii ⁇ g ⁇ n ⁇ si ⁇ elem is ⁇ lz ⁇ vali ads ⁇ ben ⁇ ⁇ eches ⁇ venn ⁇ y ma ⁇ i ⁇ S on ⁇ m bshi ⁇ valen ⁇ n ⁇ ⁇ i ⁇ si ⁇ vany ⁇ s ⁇ anda ⁇ n ⁇ y ⁇ imi ⁇ - ⁇ e ⁇ n ⁇ l ⁇ giches ⁇ y me ⁇ di ⁇ e ⁇ i ⁇ ⁇ uS-d ⁇ n ⁇ v, za ⁇ azhenny ⁇ is ⁇ lz ⁇ vannym 40
  • a single compartment with an indicated immune bind was connected to a single-type silicone tubing that was connected to a portable device; at its uchas ⁇ a ⁇ ⁇ azmeschalis ⁇ alchi ⁇ vy ( ⁇ b ⁇ u ⁇ atsi ⁇ nny) lab ⁇ a ⁇ ny nas ⁇ s neb ⁇ lsh ⁇ y m ⁇ schn ⁇ s ⁇ i, ⁇ ab ⁇ avshy in ⁇ ezhime ⁇ ds ⁇ sa ⁇ vi of ⁇ l ⁇ n ⁇ i and ⁇ eguli ⁇ uemy with ⁇ m ⁇ schyu ⁇ e ⁇ s ⁇ a ⁇ a ⁇ ⁇ azaniyam ne ⁇ n ⁇ a ⁇ n ⁇ g ⁇ man ⁇ me ⁇ a ⁇ pressure sis ⁇ eme.
  • P ⁇ i ⁇ b ⁇ ab ⁇ e S ⁇ ZH is ⁇ lz ⁇ vali in ⁇ tsedu ⁇ a ⁇ ILS ⁇ susches ⁇ vu entire vyshe ⁇ isannuyu E ⁇ STSPD ⁇ i s ⁇ s ⁇ i ⁇ e ⁇ uzii li ⁇ v ⁇ a (S ⁇ ZH) 0.1 - 0.3 ml / min ⁇ i dli ⁇ eln ⁇ s ⁇ i 30 minutes the session with ⁇ n ⁇ lem s ⁇ s ⁇ i ⁇ e ⁇ uzii ⁇ s ⁇ etsialn ⁇ ⁇ is ⁇ s ⁇ blenn ⁇ y ⁇ a ⁇ elnitse and se ⁇ und ⁇ me ⁇ u; The session was repeated a day after calculating the total amount of coolant in the Central Council of Centers for each session.
  • the standard method is that they have been able to electronically study the radiation received for the infection of 10 nm (neuromuscular), and it is inactive.
  • S ⁇ glasn ⁇ za ⁇ li ⁇ vannym ⁇ ezul ⁇ a ⁇ am ⁇ vedenn ⁇ g ⁇ e ⁇ s ⁇ e ⁇ imen ⁇ a have d ⁇ n ⁇ ny ⁇ and ⁇ d ⁇ y ⁇ ny ⁇ microseconds, not ⁇ dve ⁇ gavshi ⁇ sya treatment me ⁇ d ⁇ m IGS or HUD, and ⁇ n ⁇ lny ⁇ B ⁇ , s ⁇ ve ⁇ s ⁇ venn ⁇ , che ⁇ ez 2 - 3 months and che ⁇ ez ⁇ din month ⁇ sle za ⁇ azheniya were za ⁇ egis ⁇ i ⁇ vany ⁇ yavleniya ⁇ azheniya TS ⁇ S, ⁇ ye s ⁇ s ⁇ yali in neus ⁇ ychiv ⁇ s ⁇ i ⁇ zy ⁇ ela lively, in a limited period of time in the form of shaking the rear end, and then in the development of a rigid front and rear end with an extraordinary.

Abstract

L'invention concerne un procédé de réhabilitation des patients souffrant d'une infection virale lente (IVL) grâce à des mesures individuelles. Lors d'une IVL, la réhabilitation des malades passe par la protection contre l'infection des cellules cibles potentielles par les virions de nouvelles générations, et ce au moyen du blocage par la réplication synchrone préventive du virus déclencheur en phase de sortie des virions des cellules maîtres, suivi d'un traitement complexe et individualisé de ces virions en deux étapes subséquentes: (1) élimination du facteur pathogène et (2) rétablissement du potentiel immunitaire perturbé du malade. L'invention permet de réhabiliter l'organisme qui a été soumis à des virus classiques, du type du virus d'herpès, du virus de l'immundéficience humaine, du virus de l'hépatite C, etc. ainsi que des virus non traditionnels du type de prions.
PCT/RU2002/000143 2001-11-08 2002-04-01 Procede de rehabilitation de l'organisme en cas d'infection virale lente WO2003040723A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2001129826 2001-11-08
RU2001129826/14A RU2207876C1 (ru) 2001-11-08 2001-11-08 Способ комплексно-индивидуализированного воздействия на организм при медленной вирусной инфекции и способ подготовки лабораторного животного для испытания способа такого воздействия

Publications (1)

Publication Number Publication Date
WO2003040723A1 true WO2003040723A1 (fr) 2003-05-15

Family

ID=20254144

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/RU2002/000143 WO2003040723A1 (fr) 2001-11-08 2002-04-01 Procede de rehabilitation de l'organisme en cas d'infection virale lente

Country Status (2)

Country Link
RU (1) RU2207876C1 (fr)
WO (1) WO2003040723A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102494979A (zh) * 2011-10-19 2012-06-13 北京工业大学 一种污泥沉降体积指数svi的软测量方法

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005004904A1 (fr) * 2003-07-14 2005-01-20 Dmitry Dmitrievich Genkin Methode de traitement de maladies s'accompagnant d'alterations de la composition qualitative et/ou quantitative de l'adn extracellulaire du sang (variantes)
US8431123B2 (en) 2003-07-14 2013-04-30 Cls Therapeutics Limited Method for treating systemic bacterial, fungal and protozoan infection
EP1666055A4 (fr) * 2003-07-14 2010-02-10 Viktor Veniaminovich Tets Methode de traitement des maladies oncologiques, infectieuses et somatiques, procedes de controle de l'efficacite du traitement, agents et compositions pharmaceutiques associes
US8710012B2 (en) 2003-07-14 2014-04-29 Cls Therapeutics Limited Method for treating oncological diseases
US8388951B2 (en) 2003-07-14 2013-03-05 Cls Therapeutics Limited Method for treating systemic DNA mutation disease
US8916151B2 (en) 2005-04-25 2014-12-23 Cls Therapeutics Limited Method for treating a reduction of fertility
PL2095825T3 (pl) 2006-11-28 2011-12-30 Cls Therapeutics Ltd Sposób leczenia ludzkich chorób związanych ze zwiększoną zawartością kwasu deoksyrybonukleinowego w przestrzeniach pozakomórkowych i tkankach i preparat leczniczy do przeprowadzenia tego sposobu
US10617743B2 (en) 2014-06-19 2020-04-14 Cls Therapeutics Limited Method to improve safety and efficacy of anti-cancer therapy
EP3297657B1 (fr) 2015-05-22 2020-03-25 GENKIN, Dmitry Dmitrievich Adn extracellulaire en tant que cible thérapeutique dans la neurodégénérescence
EP3740581A4 (fr) 2018-01-16 2021-10-27 CLS Therapeutics Limited Traitement de maladies par expression hépatique d'une enzyme qui a une activité désoxyribonucléase (dnase)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990012578A1 (fr) * 1989-04-21 1990-11-01 Cornell Research Foundation, Inc. Procede d'inhibition de l'induction d'infections virales latentes ou chroniques
RU2105310C1 (ru) * 1995-12-21 1998-02-20 Виталий Васильевич Ткаченко Способ лечения синдрома приобретенного иммунного дефицита (спид)
RU2146930C1 (ru) * 1998-04-10 2000-03-27 Ткаченко Виталий Васильевич Способ лечения вич-инфекции
WO2001037868A1 (fr) * 1999-11-24 2001-05-31 Oklahoma Medical Research Foundation Analyses et therapies utilisees dans le cas d'une infection virale latente

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990012578A1 (fr) * 1989-04-21 1990-11-01 Cornell Research Foundation, Inc. Procede d'inhibition de l'induction d'infections virales latentes ou chroniques
RU2105310C1 (ru) * 1995-12-21 1998-02-20 Виталий Васильевич Ткаченко Способ лечения синдрома приобретенного иммунного дефицита (спид)
RU2146930C1 (ru) * 1998-04-10 2000-03-27 Ткаченко Виталий Васильевич Способ лечения вич-инфекции
WO2001037868A1 (fr) * 1999-11-24 2001-05-31 Oklahoma Medical Research Foundation Analyses et therapies utilisees dans le cas d'une infection virale latente

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
G. YA SINAYA ET AL., 1949, MOSCOW, MEDGIZ, article "Mikrobiologicheskie metody issledovaniya pri infektsionnykh zabolevaniyakh", pages: 171 *
KETTI D., 1991, MOSCOW, article "Antitelya metody" *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102494979A (zh) * 2011-10-19 2012-06-13 北京工业大学 一种污泥沉降体积指数svi的软测量方法

Also Published As

Publication number Publication date
RU2207876C1 (ru) 2003-07-10

Similar Documents

Publication Publication Date Title
WO2003040723A1 (fr) Procede de rehabilitation de l'organisme en cas d'infection virale lente
WO1984002470A1 (fr) Preparation medicinale pour le traitement therapeutique d'ulceres peptiques
WO2005007187A1 (fr) Methode de traitement des maladies oncologiques, infectieuses et somatiques, procedes de controle de l'efficacite du traitement, agents et compositions pharmaceutiques associes
WO1994001099A1 (fr) Composition pharmaceutique presentant des actions anti-alcool stimulant le metabolisme de l'energie, stimulant les fonctions de production et de secretion d'acide de la membrane muqueuse de l'estomac, et presentant egalement des actions radioprotectrice et anti-cholera
Klesius et al. Bovine transfer factor: in vivo transfer of cell-mediated immunity to cattle with alcohol precipitates
WO1993013764A1 (fr) Preparation pharmaceutique a action antistress, de prevention du stress et nootrope
WO2003072124A1 (fr) Methode d'induction de differentiation cellulaire
WO2005004789A2 (fr) Methode de traitement de maladies s'accompagnant d'alterations de la composition qualitative ou quantitative de l'adn extracellulaire du sang
WO2004043485A1 (fr) Composition presentant des proprietes antioxydantes, procede de production d'un polypeptide et methode de traitement
WO2005004904A1 (fr) Methode de traitement de maladies s'accompagnant d'alterations de la composition qualitative et/ou quantitative de l'adn extracellulaire du sang (variantes)
WO1989005660A1 (fr) Preparation pharmaceutique pour la prophylaxie individuelle des maladies veneriennes et pour traiter la trichomonase urogenitale
Uwaydah et al. Treatment of typhoid fever with cefamandole
WO2004064849A1 (fr) Produit normalisant la structure et les fonctions des organes et tissus, stimulant les reparations des lesions et possedant une activite antivirale
WO1995008318A2 (fr) Substance medicinale a proprietes anti-infecteuses destinee a etre utilisee dans le traitement de la sterilite et dans la protection de la grossesse
Drinkwater Fifty years of medical progress, 1873-1922
WO2004022079A1 (fr) Procede de reinstallation d'un systeme de controle de l'homeostasie antigenique d'organismes de mammiferes (effet de koukhartchouk-radtchenko-sirman)
Spink et al. Encephalomeningitis due to Brucella abortus
CN106539816A (zh) 环二核苷酸在防治多发性硬化症中的应用
CN106539815A (zh) 环二核苷酸在防治多发性硬化症中的应用
WO1989002745A1 (fr) Preparation pharmaceutique de traitement de la sclerose en plaques et de la sclerose laterale amyotrophique
Keesey The most vulnerable synapse: historic aspects of neuromuscular junction disorders
WO1999016456A1 (fr) Preparation ayant une activite biologique, complexe de preparations et procede de stimulation immunologique
WO2002092066A1 (fr) Preparation antitumorale sans effets secondaires
Potter FUNCTIONAL TESTS IN EXPERIMENTAL TARTRATE NEPHRITIS. ą
Sherman Vaccine therapy in general practice

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: RULE 69(1) EPC

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP